---
title: "Humanwell Healthcare (Group) Co.,Ltd. (600079.SH)"
type: "Symbol"
locale: "en"
url: "https://longbridge.com/en/quote/600079.SH.md"
symbol: "600079.SH"
name: "Humanwell Healthcare (Group) Co.,Ltd."
industry: "Pharmaceuticals"
datetime: "2026-04-15T09:30:13.208Z"
locales:
  - [en](https://longbridge.com/en/quote/600079.SH.md)
  - [zh-CN](https://longbridge.com/zh-CN/quote/600079.SH.md)
  - [zh-HK](https://longbridge.com/zh-HK/quote/600079.SH.md)
---

# Humanwell Healthcare (Group) Co.,Ltd. (600079.SH)

## Company Overview

Humanwell Healthcare (Group) Co.,Ltd. researches, develops, produces, and sells pharmaceutical products in China and internationally. The company offers sufentanil citrate injection, an analgesic drug for combined anesthesia; remifentanil hydrochloride injection for induction of general anesthesia and maintenance of analgesia during general anesthesia; hydromorphone hydrochloride injection for patients who require opioid analgesia; nabuphine hydrochloride injection for use as an analgesic for anesthesia induction; alfentanil hydrochloride injection, a narcotic analgesic; remizaren besylate injection for sedation and anesthesia during non-endotracheal intubation surgery; and mifepristone preparations for pregnancy prevention or termination. It also provides zuka wood particles for colds; compound muniziqi granules to treat skin and gynecologicalconditions; urokinase injection for thromboembolic diseases; and neomycin sulfate API for the prevention and treatment of intestinal diseases in animals.

| Item | Detail |
|------|--------|
| Industry | Pharmaceuticals |
| Exchange | CN Market |
| Website | [www.humanwell.com.cn](https://www.humanwell.com.cn) |

## Key Drivers
> *AI-analyzed key factors driving this stock's performance*


## Longbridge Financial Score™: C
> *Longbridge Financial Score™ — Proprietary multi-factor rating model by Longbridge*
> Updated: 2026-04-15T04:30:12.000Z

**Overall: C (0.43)**

**Industry**: Pharmaceuticals

| Metric | Value |
|--------|-------|
| Industry Ranking | 74 / 222 |
| Industry Median | C |
| Industry Average | C |

- **Style**: Value - Stocks where the company's main business is in a mature stage.
- **Scale**: Mid - The company has stable operation of a large-cap stock and the high return of a small-cap stock.

**Multi Score**: C

#### Style Score Score: 

| Indicator | Value | Rating |
|-----------|-------|--------|
| Revenue YoY | -5.79% |  |
| Net Profit YoY | 39.53% |  |
| P/B Ratio | 1.60 |  |
| Dividend Ratio | 1.73% |  |

#### Size Score Score: 

| Indicator | Value | Rating |
|-----------|-------|--------|
| Market Cap | 30195458221.67 |  |
| Revenue | 23909740385.15 |  |

#### Multi Score Score: C

| Indicator | Value | Rating |
|-----------|-------|--------|
| ROE | 10.16% | B |
| Profit Margin | 7.74% | B |
| Gross Margin | 48.11% | B |
| Revenue YoY | -5.79% | D |
| Net Profit YoY | 39.53% | B |
| Total Assets YoY | 0.65% | C |
| Net Assets YoY | 6.35% | B |
| Cash Flow Margin | 135.76% | B |
| OCF YoY | -5.79% | D |
| Turnover | 0.65 | B |
| Gearing Ratio | 40.11% | C |

```chart-data:radar
{
  "title": "Longbridge Financial Score - Humanwell Healthcare (Group) Co.,Ltd.",
  "chart_type": "radar",
  "dimensions": [
    {
      "name": "Style Score",
      "grade": "",
      "indicators": [
        {
          "name": "Revenue YoY",
          "value": "-5.79%",
          "rating": ""
        },
        {
          "name": "Net Profit YoY",
          "value": "39.53%",
          "rating": ""
        },
        {
          "name": "P/B Ratio",
          "value": "1.60",
          "rating": ""
        },
        {
          "name": "Dividend Ratio",
          "value": "1.73%",
          "rating": ""
        }
      ]
    },
    {
      "name": "Size Score",
      "grade": "",
      "indicators": [
        {
          "name": "Market Cap",
          "value": "30195458221.67",
          "rating": ""
        },
        {
          "name": "Revenue",
          "value": "23909740385.15",
          "rating": ""
        }
      ]
    },
    {
      "name": "Multi Score",
      "grade": "C",
      "indicators": [
        {
          "name": "ROE",
          "value": "10.16%",
          "rating": "B"
        },
        {
          "name": "Profit Margin",
          "value": "7.74%",
          "rating": "B"
        },
        {
          "name": "Gross Margin",
          "value": "48.11%",
          "rating": "B"
        },
        {
          "name": "Revenue YoY",
          "value": "-5.79%",
          "rating": "D"
        },
        {
          "name": "Net Profit YoY",
          "value": "39.53%",
          "rating": "B"
        },
        {
          "name": "Total Assets YoY",
          "value": "0.65%",
          "rating": "C"
        },
        {
          "name": "Net Assets YoY",
          "value": "6.35%",
          "rating": "B"
        },
        {
          "name": "Cash Flow Margin",
          "value": "135.76%",
          "rating": "B"
        },
        {
          "name": "OCF YoY",
          "value": "-5.79%",
          "rating": "D"
        },
        {
          "name": "Turnover",
          "value": "0.65",
          "rating": "B"
        },
        {
          "name": "Gearing Ratio",
          "value": "40.11%",
          "rating": "C"
        }
      ]
    }
  ]
}
```

## Valuation Analysis

| Metric | Current | Industry Ranking | High | Median | Low |
|--------|---------|-----------------|------|--------|-----|
| PE (TTM) | 16.31 | 20/222 | 25.30 | 24.11 | 21.01 |
| PB | 1.60 | 42/222 | 1.91 | 1.84 | 1.62 |
| PS (TTM) | 1.26 | 12/222 | 1.40 | 1.34 | 1.27 |
| Dividend Yield | 1.73% | 74/222 | 2.30% | 1.73% | 1.54% |

## Peer Comparison

| Rank | Name | Profit | Growth | Operation | Security | Cash | Rating |
| --- | --- | --- | --- | --- | --- | --- | --- |
| 01 | Xingqi Pharmaceutical (300573.SZ) | A | A | A | B | B | A |
| 02 | Hengrui Pharma (600276.SH) | A | B | C | A | B | B |
| 03 | Yunnan Baiyao (000538.SZ) | B | C | B | B | C | B |
| 04 | Salubris (002294.SZ) | B | C | C | A | B | B |
| 05 | Haisco (002653.SZ) | B | C | E | A | A | B |

## Institutional View

### Analyst Rating Distribution

> As of 2025-11-04T16:00:00.000Z

Total Analysts: **1**

| Rating | Count | Percentage |
|--------|-------|-----------| 
| Hold | 1 | 100% |

### Target Price Forecast

| Metric | Price |
|--------|-------|
| Current Price | 18.79 |
| Highest Target | 22.21 |
| Lowest Target | 22.21 |

## References

- [Company Overview — Profile, executives, shareholders, business breakdown](https://longbridge.com/en/quote/600079.SH/overview.md)
- [Financial Reports — Income, balance sheet, cash flow, dividends](https://longbridge.com/en/quote/600079.SH/norm.md)
- [Related News](https://longbridge.com/en/quote/600079.SH/news.md)
- [Filings — Company announcements and regulatory filings](https://longbridge.com/en/quote/600079.SH/filings.md)

---

> **Disclaimer: This article is for reference only and does not constitute any investment advice.**